Nicox SA provided an update on Fera’s evaluation of naproxcinod for future development. Fera have been reviewing opportunities for the development of naproxcinod in a number of indications and have conducted pre-clinical development work on naproxcinod in models of both COVID-19 infections and sickle cell disease. Taking into consideration the data to date in the COVID-19 models and the environment for development of COVID-19 therapeutics, Fera has decided to no longer continue this route of evaluation. Efforts will continue focusing on sickle cell disease, where Fera has submitted a new application for Orphan Drug Designation (ODD) for naproxcinod in sickle-cell disease, addressing the concerns raised by the U.S. Food and Drug Administration in their refusal letter to the previous application, and other undisclosed therapeutic indications where the properties of naproxcinod may be beneficial.